(Q39176539)

English

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

scientific article published on 17 November 2016

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Gerd-Rüdiger Burmester

10

object named as

Gerd R Burmester

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

author name string

Roy Fleischmann

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Janet van Adelsberg

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Yong Lin

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Geraldo da Rocha Castelar-Pinheiro

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Jan Brzezicki

5

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Pawel Hrycaj

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Neil M H Graham

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Hubert van Hoogstraten

8

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Deborah Bauer

9

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

publication date

17 November 2016

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

69

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

277-290

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Interleukin-6 and chronic inflammation

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

The biology and medical implications of interleukin-6.

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

The role of interleukin 6 in the pathophysiology of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Interleukin-6: discovery of a pleiotropic cytokine

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Interleukin 6 and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Total cholesterol and LDL levels decrease before rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Extra-articular manifestations and complications of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

https://api.crossref.org/works/10.1002%2FART.39944

21 January 2018

How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27860410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine production by synovial T cells in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27860410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane

1 reference

https://pubmed.ncbi.nlm.nih.gov/27860410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum Interleukin-6 Level is a Sensitive Parameter of Disease Activity in Rheumatoid Arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27860410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of s

1 reference

https://pubmed.ncbi.nlm.nih.gov/27860410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/27860410

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.39944

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39176539&oldid=1811885619"